Background Recurrent venous thromboembolism (VTE) is common. Current guidelines
suggest that patients with unprovoked VTE should continue anticoagulants unless they have …

Background Non‐valvular atrial fibrillation (NVAF) patients are advised to switch from a
vitamin K antagonist (VKA) to direct oral anticoagulant (DOAC) when time in therapeutic …

Background In January 2021, the Dutch vaccination program against severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) was started. Clinical studies have shown …

Background The pathophysiology of chronic thromboembolic pulmonary hypertension
(CTEPH) is not fully understood. Poor-quality anticoagulation may contribute to a higher risk …

Abstract Introduction The European Medicine Agency has authorized COVID-19 vaccination
in adolescents and young adults (AYAs) from 12 years onwards. In elderly vitamin K …

Background Several models are available to predict recurrent venous thrombosis (VT) in
patients with unprovoked first events. Objectives To validate these prediction models …

Objectives To analyse the effect on therapeutic control and self-management skills of the
implementation of self-management programmes, including eHealth by e-learning versus …

Background Selective serotonin reuptake inhibitors (SSRIs) may increase the risk of major
bleeding by decreasing platelet function or decreasing vitamin K antagonist (VKA) …

Research results are conflicting on whether the single nucleotide polymorphism rs9923231
(− 1639G> A) of vitamin K epoxide reductase complex subunit-1 (VKORC1) is associated …

Background Major bleeding occurs annually in 1%–3% of patients on vitamin K antagonists
(VKAs), despite close monitoring. Genetic variants in proteins involved in VKA response may …